Skip to main content
Premium Trial:

Request an Annual Quote

Up, Up, Up


According to Cancer Research UK, cancer diagnoses in men and women aged 40 to 59 have risen by nearly 20 percent in a generation in the UK, reports the Guardian's Sarah Boseley. Part of that is due to more sophisticated screening methods that are able to pick up more cancers. But the other reason for the rise in diagnoses is that smoking, drinking, and obesity continues to plague middle-aged men and women, Boseley says. According to a Cancer Research UK report, the incidence of cancer has risen from 328 cases per 100,000 40 to 59 year olds in 1979, to 388 per 100,000 in 2008. That equals to 17,000 additional cancer cases being diagnosed in the UK each year for that age group, Boseley says. Women have seen a bigger rise in diagnoses than men. But advanced screening methods also mean more cancers are being detected and treated earlier, which saves lives, she adds. Survival rates have also gone up since the 1970s. Now, says Cancer Research UK, a change in lifestyle is needed — less sun exposure, unhealthy foods, smoking, and drinking, and more exercise.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.